JAKARTA - PT Bio Farma (Persero), the holding company of the Pharmaceutical SOE, exported the Novel Oral Polio Vaccine type 2 (nOPV2) vaccine to a number of countries in Africa, Europe, and the Middle East after obtaining a request contract from UNICEF for 2022 and 2023.
"Saat ini yang membeli produk nOPV2 tersebut adalah UNICEF, secara ber multilateral. Vaksin nOPV2 menjadi salah satu cara untuk mencegah perluasan wabah offiseo di dunia. Dengan keberhasil Bio Farma memproduksi dan menekspor vaksin nOPV2, kami telah berkontribusi pada kesehatan global sekaligus mampu menyiapkan pendapatan (stockpile) bagi kebutuhan dunia," ujar Direktur Utama Bio Farma Honesti Basyir lewat rilis di Bandung, dikutip dari Antara, Rabu, 28 September.
Honesti said that the distribution of polio vaccine to various countries was carried out by Bio Farma after UNICEF issued PO (Purchasing Order) for vaccine delivery.
The nOPV2 vaccine has received a use permit in emergency conditions from the Food and Drug Administration (BPOM) and the Emergency Use of Listing (EUL) from the World Health Organization (WHO).
nOPV2 users include Cameroon, Congo, DjiAbouti, Ethiopia, Gambia, Ghana, Nigeria, Senegal, and Uganda (Africa). Then Israel and Ukraine, as well as Egypt, Iran, Somalia, and Yemen (Central East).
He said the production of the nOPV2 vaccine was the result of collaboration between Bio Farma and world research institutions such as the Bill and Melinda Gates Foundation (BMGF), PATH, and WHO.
In addition to producing the polio vaccine, Bio Farma is also a reference laboratory for examining each sample of the polio virus.
Honesti further conveyed that Bio Farma's contribution in providing the polio vaccine was in line with one of the priority issues that will be discussed in the G20 Presidency, namely global health development.
Through the momentum of the G20 Presidency, he said, Indonesia also showed success in controlling the COVID-19 pandemic and Bio Farma became one of the front lines in vaccination in the country.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
